human plasma protein
PolandDrugs containing this active substance
-
The medicine is used to restore blood volume in patients in whom a deficiency has been identified.
Form: solution for infusion
Active substance Dosage human plasma protein 200 g ATC: B05AA01
-
The medicinal product is used for the treatment and prevention of bleeding in individuals with hemophilia A or B who have factor VIII or IX inhibitors. It may also be used in individuals without hemophilia who have acquired inhibitors of factors VIII, IX, or XI, and to assist in the complete elimination of factor VIII inhibitors during long-term treatment.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human plasma protein 20-60 mg/ml ATC: B02BD03
Manufacturer: Takeda Manufacturing Austria AG
-
The medicinal product is used for the treatment and prevention of bleeding in patients with haemophilia A or B who have a factor VIII or IX inhibitor. It may also be used in individuals without haemophilia but with acquired inhibitors of factors VIII, IX, and XI, and to assist in the complete elimination of factor VIII inhibitors during long-term treatment.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human plasma protein 20-60 mg/1 mL factor viii inhibitor bypassing activity 50 units/1 mL ATC: B02BD03
Manufacturer: Takeda Manufacturing Austria AG
-
It is used to treat complex coagulation factor deficiencies that may result from acute liver failure or massive transfusion. It may also be administered in emergency situations to rapidly reverse the effects of anticoagulants or to restore coagulation factor balance during plasma exchange.
Form: solution for infusion
Active substance Dosage human plasma protein 9-14 g/200 ml ATC: B05AA
Manufacturer: Octapharma AB